COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
Orchestrating operational readiness across every defence domain
Are all systems ready for the next mission? Have upgrades been applied? Are all assets aligned to deploy together, on time and fully prepared? In modern defence operations, readiness is no longer measured platform by platform. It is measured by how well people, assets, data and decisions move together — across land, sea and air.
-
How deepening AI usage can boost efficiency and maximise effects for forces
Saab has outlined how it is using artificial intelligence to make training more like electronic gaming, while the UK’s Power Size Technologies is applying the same technology to better evaluate and design vehicle capability, moving AI-enabled innovation further upstream from the frontline.
-
From systems integrator to multi-domain solutions provider (video)
Philipp von Brandenstein, Head of Corporate Communications at Rheinmetall, explains how Eurosatory 2026 marked a new stage in the company's evolution.
-
US Pentagon pushes for major reform of defence acquisition system
The US Department of Defense has requested new contracting authorities from Congress, using the Army's MV-75 Cheyenne programme to demonstrate how competition, digital engineering and closer industry collaboration could accelerate acquisitions.